Cite
Impact of NAFLD and its pharmacotherapy on lipid profile and CVD.
MLA
Wang, Zhenya, et al. “Impact of NAFLD and Its Pharmacotherapy on Lipid Profile and CVD.” Atherosclerosis (00219150), vol. 355, Aug. 2022, pp. 30–44. EBSCOhost, https://doi.org/10.1016/j.atherosclerosis.2022.07.010.
APA
Wang, Z., Ye, M., Zhang, X.-J., Zhang, P., Cai, J., Li, H., & She, Z.-G. (2022). Impact of NAFLD and its pharmacotherapy on lipid profile and CVD. Atherosclerosis (00219150), 355, 30–44. https://doi.org/10.1016/j.atherosclerosis.2022.07.010
Chicago
Wang, Zhenya, Mao Ye, Xiao-Jing Zhang, Peng Zhang, Jingjing Cai, Hongliang Li, and Zhi-Gang She. 2022. “Impact of NAFLD and Its Pharmacotherapy on Lipid Profile and CVD.” Atherosclerosis (00219150) 355 (August): 30–44. doi:10.1016/j.atherosclerosis.2022.07.010.